- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03744156
Sleep and Pain Interventions in Women With Fibromyalgia (SPIN-II)
Impact of CBT for Insomnia on Pain Symptoms and Central Sensitization in Fibromyalgia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Sydney D Shoemaker, MS
- Phone Number: (573) 882-5113
- Email: sds3mk@umsystem.edu
Study Locations
-
-
Missouri
-
Columbia, Missouri, United States, 65210
- Recruiting
- University of Missouri- Department of Psychiatry
-
Principal Investigator:
- Christina McCrae, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- female
- 18+ years of age
- willing to be randomized
- can read and understand English
- diagnosed with Fibromyalgia and insomnia
- no prescript or over the counter pain or sleep medicaments for 1+ month
Exclusion Criteria:
- unable to provide informed consent
- cognitive impairment
- sleep disorder other than insomnia (i.e., sleep apnea, periodic limb movement disorder
- bipolar or seizure disorder
- other major psychopathology (other than depression or anxiety)
- psychotropic or other medications that alter pain or sleep
- participation in non-pharmacological treatment (including CBT) for pain, sleep, or mood outside current trial
- internal metal objects or electrical devices
- pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cognitive Behavioral Treatment-Insomnia
Cognitive Behavioral Treatment-Insomnia.
8 Session treatment focusing on behavior and cognitions related to sleep and pain.
|
8 session Cognitive Behavioral Therapy for Insomnia.
Individualized sessions with a therapist.
Other Names:
|
Experimental: Sleep Hygiene Education
Sleep Hygiene Education.
8 Session treatment focusing on sleep hygiene education.
|
8 Session Sleep Hygiene Education.
Individualized sessions with a therapist.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Self-Reported Bedtime, Wake time, Sleep Onset Latency, Wake After Sleep Onset, Sleep Quality on the Daily Diaries
Time Frame: baseline to follow-up (approximately 60 weeks)
|
Participants will answer the following questions on the daily diaries: I napped for ____________ minutes yesterday. I napped ______ times yesterday. I napped in the ___morning ___afternoon ____evening (check all that apply) I went to bed last night at ____________ AM/PM. It took me ____________ minutes to fall asleep. I woke up ____________ times last night. I was awake for ____________ minutes in the middle of the night. My final wake up time was ____________ AM/PM. I got out of bed at ____________ AM/PM. I would rate my quality of sleep last night as ____________. 1. very poor 2. poor 3. fair. 4 good 5. Excellent |
baseline to follow-up (approximately 60 weeks)
|
Change in Insomnia Severity Index (ISI)
Time Frame: baseline to follow-up (approximately 60 weeks)
|
The Insomnia Severity Index will be administered four times - baseline, post-treatment, and 6 and 12 month follow-up.
Analysis will involve examining the trend of change in the ISI.
|
baseline to follow-up (approximately 60 weeks)
|
Change in Peripheral Arousal
Time Frame: baseline to follow-up (approximately 60 weeks)
|
heart rate variability (as measured by Holter-Monitoring)
|
baseline to follow-up (approximately 60 weeks)
|
Change in Perceived Stress Scale
Time Frame: baseline to follow-up (approximately 60 weeks)
|
measures how much self-reported stress participants experience (from 0-never to 4-very often) across various 10 situations.
Higher total scores indicate greater perceived stress.
|
baseline to follow-up (approximately 60 weeks)
|
Change in Dysfunctional Beliefs and Attitudes about Sleep (DBAS)
Time Frame: baseline to follow-up (approximately 60 weeks)
|
30-item self-report questionnaire designed to identify and assess various sleep/insomnia-related cognitions (e.g., beliefs, attitudes, expectations, appraisals, attributions).
|
baseline to follow-up (approximately 60 weeks)
|
Change in Pain Catastrophizing Scale
Time Frame: baseline to follow-up (approximately 60 weeks)
|
The PCS instructions ask participants to reflect on past painful experiences, and to indicate the degree to which they experienced each of 13 thoughts or feelings when experiencing pain, on 5-point scales with the end points (0) not at all and (4) all the time.
The PCS yields a total score and three subscale scores assessing rumination, magnification and helplessness.
Total score range from 0-52, with higher scores indicating greater pain catastrophizing.
|
baseline to follow-up (approximately 60 weeks)
|
Change in self-reported ratings of Pain Sensitivity and Pain Unpleasantness on Daily Diaries
Time Frame: baseline to follow-up (approximately 60 weeks)
|
Participants will rate how much pain they experience and how unpleasant the pain is on a scale of 1 to 100 on the daily dairies.
Analysis will involve examining the trend of changes in these ratings.
|
baseline to follow-up (approximately 60 weeks)
|
Neural Imaging: Structural/Functional MRI/Diffusion Weighted Imaging
Time Frame: baseline to follow-up (approximately 60 weeks)
|
assessment of neural plasticity
|
baseline to follow-up (approximately 60 weeks)
|
Change in Bedtime, Wake time, Sleep Onset Latency, and Wake After Sleep Onset measured by Actigraphy
Time Frame: baseline to follow-up (approximately 60 weeks)
|
Actiwatch-L (ACT-L; Mini Mitter, Inc.) will be used to obtain a behavioral measure of sleep outcome.
ACT-L is a wristwatch-like device that provides long-term monitoring of ambient light exposure and gross motor activity in human subjects.
The Actiware-Sleep software provides behavioral estimates for several sleep variables: (1) sleep onset latency-interval between bedtime and sleep start; (2) total sleep time-sum of all sleep epochs within the sleep period; (3) sleep efficiency percentage- ratio of total sleep time to total time spent in bed × 100; and (4) total wake time-sum of all wake epochs within the sleep period.
|
baseline to follow-up (approximately 60 weeks)
|
Change in Thermal Pain Response
Time Frame: baseline to follow-up (approximately 60 weeks)
|
Participants will undergo quantitative sensory testing using a contact thermode applied to the volar surface of the forearm. The protocol that will assess both first pain (primarily A-delta function) and second pain (primarily C-fiber input). All thermal stimuli will be delivered using a computer-controlled Medoc Thermal Sensory Analyzer (TSA-2001, Ramat Yishai, Israel). Visual Analog Scale (VAS) ratings of 4 graded intensities (45, 47, 49, 51° C) of 5 second temperature stimuli will be obtained in the following fashion: Stimulus presentation will be timed such that no site is stimulated with less than a 3-minute interval to avoid sensitization of the site. Participants will rate 8 stimuli (2 at each intensity) using a VAS for pain intensity anchored at the right end by "the most intense pain imaginable." A second random sequence of 8 stimuli (2 at each intensity) will be rated by VAS for pain unpleasantness. |
baseline to follow-up (approximately 60 weeks)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Polysomnographically assessed sleep onset, wake time after sleep onset, sleep efficiency, number of awakenings, total sleep time, and sleep stage %.
Time Frame: baseline to follow-up (approximately 60 weeks)
|
Ambulatory Polysomnography will be conducted four times at baseline, post-treatment, 6-month, and 12 month follow-up.
This involves attachment of small electrodes and wires to the head and body.
|
baseline to follow-up (approximately 60 weeks)
|
Change in pain severity assessed by the McGill Pain Questionnaire
Time Frame: baseline to follow-up (approximately 60 weeks)
|
The McGill Pain Questionnaire will be administered four times - baseline, post-treatment, 6 month and 12 month follow-up.
Analysis will involve examining the trend of change in the scores in McGill Pain Questionnaire.
|
baseline to follow-up (approximately 60 weeks)
|
Change in pain-associated disability assessed by the Pain Disability Questionnaire
Time Frame: baseline to follow-up (approximately 60 weeks)
|
The Pain Disability Questionnaire will be administered four times - baseline, post-treatment, 6 month follow-up and 12-month follow-up.
Analysis will involve examining the trend of change in the scores in Pain Disability Questionnaire.
|
baseline to follow-up (approximately 60 weeks)
|
Change in Beck Depression Inventory-Second Edition
Time Frame: baseline to follow-up (approximately 60 weeks)
|
This 21-item scale measures self-reported depressive symptoms.
Total scores range from 0-63, with higher scores indicating greater maladjustment.
|
baseline to follow-up (approximately 60 weeks)
|
Change in State-Trait Anxiety Inventory-Form Y1 (STAI-YI)
Time Frame: baseline to follow-up (approximately 60 weeks)
|
The STAI-Y1 contains 20 items for assessing trait anxiety and 20 for state anxiety.
State anxiety items include: "I am tense; I am worried" and "I feel calm; I feel secure."
Trait anxiety items include: "I worry too much over something that really doesn't matter" and "I am content; I am a steady person."
All items are rated on a 4-point scale (e.g., from "Almost Never" to "Almost Always").
Higher scores indicate greater anxiety.
|
baseline to follow-up (approximately 60 weeks)
|
Change in Pain Anxiety Symptoms Scale
Time Frame: baseline to follow-up (approximately 60 weeks)
|
A 20 item self-report scale that measures the frequency (0-never, to 5-almost always) of anxiety across situations in which pain is experienced.
Total scores range from 0 to 100 with higher scores indicating greater anxiety related to pain.
|
baseline to follow-up (approximately 60 weeks)
|
Change in Anxiety and Preoccupation about Sleep Questionnaire
Time Frame: baseline to follow-up (approximately 60 weeks)
|
A 10-item scale that asks participants to rate the level of worry and/or anxiety during several situations regarding disturbed sleep.
Participant rate the truthfulness of each statement according to their own experience (1-not true to 10-very true).
Higher total scores indicate greater anxiety/preoccupation about sleep.
|
baseline to follow-up (approximately 60 weeks)
|
Activities of Daily Living (ADL) - Katz ADL Scale
Time Frame: baseline to post-treatment (approximately 12 weeks)
|
A 6-item scale that measures the degree of independence on activities of daily living (1-independent; 0-dependent; activities include bathing, dressing, toileting, transferring, continence and feeding).
Higher total scores indicate greater degree of independence on ADLs
|
baseline to post-treatment (approximately 12 weeks)
|
Independent Activities of Daily Living (IADL) - Lawton IADL Scale
Time Frame: baseline to post-treatment (approximately 12 weeks)
|
A 8-item scale that measures the degree of independence in performing instrumental activities of daily living (1-independent; 0-dependent; instrumental daily activities include ability to use telephone, shopping, food preparation, housekeeping, laundry, transportation, responsibility for own medications, and finances).
Higher total scores indicate greater degree of independence on IADLs
|
baseline to post-treatment (approximately 12 weeks)
|
Cognitive Failures Questionnaire
Time Frame: baseline to post-treatment (approximately 12 weeks)
|
A 25-item scale measuring subjective cognition; caregivers rate on a scale of 0 (never) to 4 (very often) how often they experience cognitive mistakes and errors in daily tasks
|
baseline to post-treatment (approximately 12 weeks)
|
Cognition - NIH Toolbox
Time Frame: baseline to post-treatment (approximately 12 weeks)
|
A 20-minute computerized battery completed in a single setting on iPad (20 in.
screen); domains tested include processing speed and attention, visuospatial ability and memory, verbal learning and memory, and executive functioning and working memory
|
baseline to post-treatment (approximately 12 weeks)
|
Hair Extraction
Time Frame: baseline to post-treatment (approximately 12 weeks)
|
Hair sample analysis for the inflammatory and stress hormone cortisol, and sex hormones estradiol and testosterone
|
baseline to post-treatment (approximately 12 weeks)
|
Biomarkers - Neurodegeneration and Inflammation
Time Frame: baseline to post-treatment (approximately 12 weeks)
|
Blood based biomarkers and hormones will be examined at each assessment period; biomarkers include CRP & IL-6, AβB42, AβB40 & total tau and phosphorylated-Tau at threonine181 & threonine217
|
baseline to post-treatment (approximately 12 weeks)
|
Plasma-Based Hormones
Time Frame: baseline to post-treatment (approximately 12 weeks)
|
Blood plasma analysis of three hormones including estradiol, testosterone, and cortisol
|
baseline to post-treatment (approximately 12 weeks)
|
Global Cognition - Mini Mental Status Exam (MMSE)
Time Frame: baseline to follow-up (approximately 60 weeks)
|
An 11-item questionnaire that provides a measure of global cognition.
Participants are asked questions related to orientation to time/place, memory immediate/ delayed recall, attention and calculation, naming, repetition, comprehension, reading, writing, and drawing.
Participants are scored 0-incorrect or 1- correct on each item.
Total score is computed (out of 30), with higher total scores indicating better global cognitive function.
|
baseline to follow-up (approximately 60 weeks)
|
Global Cognition - Montreal Cognitive Assessment (MoCA)
Time Frame: baseline to post-treatment (approximately 12 weeks)
|
A 30-item questionnaire that provides a measure of global cognition.
Participants are asked questions related to visuospatial/executive functioning, naming, memory immediate/delayed recall, attention, language, abstraction, and orientation to time/place.
Participants are scored 0-incorrect or 1-correct on each item.
Total score is computed (out of 30), with higher total scores indicating better global cognitive function.
|
baseline to post-treatment (approximately 12 weeks)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Christina McCrae, PhD, University of Missouri-Columbia
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2011835
- 1R01NR017168-01A1 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Insomnia
-
Leiden UniversityBioClock Consortium; Caring UniveristiesCompleted
-
National Science Council, TaiwanCompleted
-
Sunshine Lake Pharma Co., Ltd.Unknown
-
Pfizer's Upjohn has merged with Mylan to form Viatris...Completed
-
Massachusetts General HospitalNational Institutes of Health (NIH)Completed
-
IpsenCompletedThe Effectiveness of Circadin in Improving Quality of Sleep in Patients Aged 55 or Over (QUALISLEEP)InsomniaRussian Federation
-
Charite University, Berlin, GermanyCompleted
-
Roxane LaboratoriesCompleted
-
Butler HospitalSunovionCompleted
Clinical Trials on Cognitive Behavioral Treatment-Insomnia
-
VU University of AmsterdamSlaapmakendCompleted
-
University of PennsylvaniaCompleted
-
US Department of Veterans AffairsTerminated
-
Brigham and Women's HospitalRecruiting
-
VA Pittsburgh Healthcare SystemVA Office of Research and DevelopmentCompleted
-
VU University of AmsterdamCompleted
-
Johns Hopkins UniversityNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedOsteoarthritis | Sleep Initiation and Maintenance DisordersUnited States
-
University of California, San FranciscoNational Institute of Mental Health (NIMH)CompletedPost-Traumatic Stress DisorderUnited States
-
Dartmouth-Hitchcock Medical CenterRecruitingInsomnia | Crohn DiseaseUnited States
-
Johns Hopkins UniversityDepartment of Defense Congressionally Directed Medical Research ProgramNot yet recruitingDepression | Insomnia | Sleep | Traumatic Brain Injury | Memory Impairment | Head Injury | Cognitive Behavioral Therapy | Concussion, Brain | Post-traumatic Stress | Brain Injury Traumatic Mild